KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Sep 2025 value amounting to $136.0 million.

  • Teva Pharmaceutical Industries' Capital Expenditures fell 8.11% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.0 million, marking a year-over-year change of 0.00%. This contributed to the annual value of $498.0 million for FY2024, which is 5.32% down from last year.
  • Teva Pharmaceutical Industries' Capital Expenditures amounted to $136.0 million in Q3 2025, which was up 41.67% from $96.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' Capital Expenditures' 5-year high stood at $157.0 million during Q1 2022, with a 5-year trough of $96.0 million in Q2 2025.
  • Its 3-year average for Capital Expenditures is $125.7 million, with a median of $127.0 million in 2025.
  • Its Capital Expenditures has fluctuated over the past 5 years, first grew by 22.13% in 2023, then decreased by 18.49% in 2024.
  • Teva Pharmaceutical Industries' Capital Expenditures (MRQ) stood at $153.0 million in 2021, then decreased by 7.19% to $142.0 million in 2022, then fell by 16.20% to $119.0 million in 2023, then increased by 8.40% to $129.0 million in 2024, then grew by 5.43% to $136.0 million in 2025.
  • Its last three reported values are $136.0 million in Q3 2025, $96.0 million for Q2 2025, and $127.0 million during Q1 2025.